Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer
Conditions: Refractory Metastatic Colorectal Cancer Interventions: Drug: Nimotuzumab injection; Drug: Placebo; Drug: Trifluridine/tipiracil Sponsors: Biotech Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Conditions: Non-Small-Cell Lung Cancer Interventions: Drug: Vebreltinib; Drug: PLB1004 Sponsors: Avistone Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus Interventions: Biological: RJMty19 (CD19-CAR-DNT cells) Sponsors: Guangdong Ruishun Biotech Co., Ltd; RenJi Hospital; Peking University People ' s Hospital; Changhai Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years
Conditions: Herpes Zoster Interventions: Biological: LYB004 25 µg; Biological: LYB004 50µg; Biological: SHINGRIX Sponsors: Guangzhou Patronus Biotech Co., Ltd.; Yantai Patronus Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials
Intratumoral CAN2109 in Subjects With Solid Tumors or Lymphomas
Conditions: Solid Tumor; Lymphoma Interventions: Drug: CAN2109 Sponsors: Canwell Biotech Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma
Conditions: Cervical Cancer Interventions: Biological: Nimotuzumab; Drug: Cisplatin; Radiation: External Beam Radiotherapy (EBRT); Radiation: Brachytherapy; Drug: placebo for Nimotuzumab Sponsors: Biotech Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
Conditions: Blood Sugar; High; Overweight and Obesity; Fat Burn; Obesity Interventions: Dietary Supplement: GLP1 Booster (GB) Sponsors: Alpine Biotech LLC Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
AAV Gene Therapy Clinical Study in Adult Classic PKU
Conditions: Phenylketonurias Interventions: Genetic: NGGT002 Sponsors: NGGT (Suzhou) Biotechnology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
Conditions: Japanese Encephalitis; Measles; Mumps; Rubella Interventions: Biological: Vero cell-drived inactive Japanese encephalitis vaccine; Biological: Measles-Mumps-Rubella Vaccine Sponsors: Liaoning Chengda Biotechnology CO., LTD Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome
Conditions: Carpal Tunnel Syndrome Interventions: Procedure: Sono-guided injection with ES135; Procedure: Sono-guided injection with placebo Sponsors: Tri-Service General Hospital; Eusol Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Conditions: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-Essential Thrombocytosis Myelofibrosis Interventions: Drug: Ruxolitinib; Drug: Tasquinimod Sponsors: M.D. Anderson Cancer Center; Active Biotech AB Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors
Conditions: Locally Advanced or Metastatic Solid Tumors Interventions: Drug: ANS014004 Sponsors: Avistone Biotechnology Co., Ltd.; Shanghai Chest Hospital; Hunan Cancer Hospital; Henan Cancer Hospital; Zhejiang Cancer Hospital; Peking University Cancer Hospital& Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 25, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 25, 2024 Category: Pharmaceuticals Source Type: clinical trials
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
Conditions: Pancreatic Cancer Interventions: Procedure: Surgery; Drug: Camrelizumab; Biological: SJ-Neo006; Drug: Gemcitabine+Abraxane Sponsors: Jinling Hospital, China; Jiangsu Synthgene Biotechnology Co.Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials
HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients
SOUTH SAN FRANCISCO, Calif.,– March 21, 2024– Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 21, 2024 Category: Pharmaceuticals Source Type: clinical trials
